Rigel to Present at Two Upcoming Investor Conferences

Rhea-AI Summary

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) announced that CFO Dean Schorno will present at two virtual investor conferences in September. The H.C. Wainwright 22^nd Annual Global Investment Conference is on September 15 at 1:00pm ET, while the Cantor Fitzgerald Virtual Global Healthcare Conference is on September 16 at 1:20pm ET. Interested parties can access the events live or view archived webcasts via Rigel's investor section on their website.

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at two virtual investor conferences in September.

Investor Presentations:
H.C. Wainwright 22^nd Annual Global Investment Conference
Date: Tuesday, September 15, 2020
Time: 1:00pm ET/10:00am PT

Cantor Fitzgerald Virtual Global Healthcare Conference 2020
Date: Wednesday, September 16, 2020
Time: 1:20pm ET/10:20am PT

To access these events live or the archived webcasts, go to the Investors section of the company's website at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE^® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product has been approved by the European Commission for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments and is marketed in Europe under the name TAVLESSE^® (fostamatinib). Fostamatinib is currently being studied in an investigator-sponsored trial conducted by Imperial College London for the treatment of COVID-19 pneumonia¹.

Rigel's clinical programs include a Phase 3 study of fostamatinib in warm autoimmune hemolytic anemia (AIHA); a completed Phase 1 study of R835¹, a proprietary molecule from its interleukin receptor associated kinase (IRAK) inhibitor program; and an ongoing Phase 1 study of R552¹, a proprietary molecule from its receptor-interacting protein kinase (RIP) inhibitor program. In addition, Rigel has product candidates in clinical development with partners AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.

Please see www.TAVALISSE.com for the full Prescribing Information.

¹The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.

IR Contact: David Burke 
Phone: 650.624.1232
Email: dburke@rigel.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-two-upcoming-investor-conferences-301126011.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

When will Rigel Pharmaceuticals present at investor conferences?

Rigel Pharmaceuticals will present on September 15, 2020, at the H.C. Wainwright 22nd Annual Global Investment Conference and on September 16, 2020, at the Cantor Fitzgerald Virtual Global Healthcare Conference.

Who is presenting for Rigel Pharmaceuticals at the conferences?

Dean Schorno, the Chief Financial Officer of Rigel Pharmaceuticals, will present at the upcoming investor conferences.

How can I access Rigel Pharmaceuticals' investor presentations?

You can access Rigel Pharmaceuticals' investor presentations live or view archived webcasts on their investor section at www.rigel.com.

What time are Rigel Pharmaceuticals' presentations at the conferences?

The presentation at the H.C. Wainwright conference is scheduled for 1:00pm ET on September 15, and at the Cantor Fitzgerald conference for 1:20pm ET on September 16, 2020.

What is Rigel Pharmaceuticals known for?

Rigel Pharmaceuticals is known for developing novel small molecule drugs for immune and hematologic disorders, including their FDA-approved product, TAVALISSE, for chronic immune thrombocytopenia.